These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2019-002949-38 A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON'S DISEASE (... 2024-06-28 bad-data
Completed, report not yet due 2019-002950-22 A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMP... 2024-10-01 not-yet-due
Listed as ongoing, but also has a completion date 2019-002951-40 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinso... 2024-02-16 bad-data
Other 2019-002952-17 58-Week Open-label Trial of Tavapadon in Parkinson's Disease (TEMPO-4 Trial) Sperimentazione in aperto della durata di 58 settimane su tavapadon nella malattia di Parkinson (Sperimentazione TEMPO-4... not-yet-due
Completed, report not yet due 2022-000580-52 A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231 in Participants With Schizophrenia E... 2024-08-26 not-yet-due
Completed, report not yet due 2022-000581-17 A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of CVL-231 in Participants With Schizophrenia E... 2024-09-11 not-yet-due
Other 2022-001151-16 A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia not-yet-due